DE69028457D1 - Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen - Google Patents

Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen

Info

Publication number
DE69028457D1
DE69028457D1 DE69028457T DE69028457T DE69028457D1 DE 69028457 D1 DE69028457 D1 DE 69028457D1 DE 69028457 T DE69028457 T DE 69028457T DE 69028457 T DE69028457 T DE 69028457T DE 69028457 D1 DE69028457 D1 DE 69028457D1
Authority
DE
Germany
Prior art keywords
physical
ranolazine
chemical damage
tissues affected
treat tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69028457T
Other languages
English (en)
Other versions
DE69028457T2 (de
Inventor
Robert J Dow
Pierre Ferrandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of DE69028457D1 publication Critical patent/DE69028457D1/de
Publication of DE69028457T2 publication Critical patent/DE69028457T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69028457T 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen Expired - Lifetime DE69028457T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (2)

Publication Number Publication Date
DE69028457D1 true DE69028457D1 (de) 1996-10-17
DE69028457T2 DE69028457T2 (de) 1997-02-20

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69033967T Expired - Lifetime DE69033967T2 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
DE69028457T Expired - Lifetime DE69028457T2 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen
DE69034000T Expired - Lifetime DE69034000T2 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zum Schutz der Skelettmuskulatur

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69033967T Expired - Lifetime DE69033967T2 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69034000T Expired - Lifetime DE69034000T2 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte Piperazine zum Schutz der Skelettmuskulatur

Country Status (13)

Country Link
US (2) US5506229A (de)
EP (3) EP0719558B1 (de)
JP (1) JP3232085B2 (de)
AT (3) ATE218344T1 (de)
AU (1) AU633589B2 (de)
CA (1) CA2019580C (de)
DE (3) DE69033967T2 (de)
DK (3) DK0719558T3 (de)
ES (3) ES2091211T3 (de)
GR (1) GR3020976T3 (de)
IE (1) IE80710B1 (de)
NZ (2) NZ234184A (de)
ZA (1) ZA904842B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6060454A (en) * 1997-08-08 2000-05-09 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
EP2033633A3 (de) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partielle Fettsäurenoxidationsinhibitoren bei der Behandlung von kongestiver Herzinsuffizienz
JP3980885B2 (ja) * 2000-02-22 2007-09-26 スィーヴィー セラピューティクス インコーポレイテッド 置換ピペラジン化合物
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
CA2420182A1 (en) * 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
CA2508608A1 (en) 2002-12-05 2004-06-24 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CA2512261A1 (en) 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2004209522A1 (en) 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
CA2530376A1 (en) 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
US7115610B2 (en) 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2005282492A1 (en) * 2004-09-08 2006-03-16 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
BRPI0517650A (pt) * 2004-11-09 2008-10-14 Cv Therapeutics Inc uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
AU2006203890A1 (en) * 2005-01-06 2006-07-13 Gilead Sciences, Inc. Sustained release pharmaceutical formulations comprising ranolazine
EP1865945A4 (de) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Kombinationstherapie bei endothel-dysfunktion, angina und diabetes
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
EP2136780A1 (de) * 2007-02-13 2009-12-30 CV Therapeutics Inc. Verwendung von ranolazin zur behandlung von herz-kreislauf-erkrankungen
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
EP2515880B1 (de) 2009-05-28 2019-11-27 Lupin Limited Neuartige pharmazeutische zusammensetzungen mit ranolazin
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
WO2011003129A1 (en) * 2009-07-09 2011-01-13 Ozteo Pty Ltd Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
US20120177729A1 (en) 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US10463611B2 (en) * 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
GB2613736A (en) * 2021-09-27 2023-06-14 Tasly Pharmaceutical Group Co Pharmaceutical composition for treating myocardial ischemia and preparation method therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
US5506229A (en) 1996-04-09
JP3232085B2 (ja) 2001-11-26
DE69034000T2 (de) 2003-06-05
JPH0348672A (ja) 1991-03-01
DK0407780T3 (da) 1996-09-30
ES2182863T3 (es) 2003-03-16
IE902250A1 (en) 1991-01-16
DK0714660T3 (da) 2002-10-07
ATE223218T1 (de) 2002-09-15
CA2019580C (en) 2007-03-27
GR3020976T3 (en) 1996-12-31
ES2177601T3 (es) 2002-12-16
IE902250L (en) 1990-12-23
DK0719558T3 (da) 2002-10-07
ATE142497T1 (de) 1996-09-15
DE69034000D1 (de) 2002-10-10
DE69028457T2 (de) 1997-02-20
NZ234184A (en) 1997-01-29
ZA904842B (en) 1992-02-26
EP0714660B1 (de) 2002-09-04
DE69033967T2 (de) 2002-12-19
NZ247044A (en) 1997-04-24
ES2091211T3 (es) 1996-11-01
EP0714660A1 (de) 1996-06-05
EP0719558A1 (de) 1996-07-03
EP0719558B1 (de) 2002-06-05
AU5761890A (en) 1991-01-03
IE80710B1 (en) 1998-12-16
DE69033967D1 (de) 2002-07-11
EP0407780A2 (de) 1991-01-16
AU633589B2 (en) 1993-02-04
EP0407780A3 (en) 1992-01-02
EP0407780B1 (de) 1996-09-11
ATE218344T1 (de) 2002-06-15
US5906988A (en) 1999-05-25
CA2019580A1 (en) 1990-12-23

Similar Documents

Publication Publication Date Title
DE69028457D1 (de) Ranolazin und verwandte Piperazine zur Behandlung von Geweben, von physischen oder chemischen Schäden betroffen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
DE58902313D1 (de) Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
ATE384703T1 (de) Piperazinyl-substituierte phenylpyrimidinderivative zur behandlung oder vorbeugung von zns erkrankungen
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
ATE111908T1 (de) Gegen allergie wirkende benzothiophene und neue und andere ausgewählte benzothiophene, beide mit wirkung zur behandlung von akuten atmungsangstanzeichen.
DE69004189D1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE95694T1 (de) Verwendung von bezafibrat zur behandlung von diabetes.
ATE250936T1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3486005D1 (de) Anwendung von carbamate oder thiocarbamat-derivaten zur behandlung von fungus-infektionen.
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE127118T1 (de) 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia.
AT366914B (de) Sterilisation oder entseuchung von apparaturen
ATE17716T1 (de) Verbindungen und methode zur behandlung oder prophylaxis von herzstoerungen.
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ATE96486T1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
ATE16178T1 (de) Methode zur behandlung oder prophylaxis von herzstoerungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition